Literature DB >> 33330752

Diabetic dyslipidemia: evaluation and mechanism.

Hidekatsu Yanai1, Yuji Hirowatari2, Hiroshi Yoshida3.   

Abstract

Diabetes is one of the well-established independent risk factors for cardiovascular diseases. Diabetes induces dyslipidemia which is characterized by elevated fasting triglyceride (TG) and reduced high-density lipoprotein-cholesterol (HDL-C), and such diabetic dyslipidemia is a crucial determinant for atherogenesis and atherosclerotic progression in patients with diabetes. Previous measurement methods of lipoproteins have problems including time-consuming (ultracentrifugation) and inaccurate and impossible measurements of TG-rich lipoproteins such as chylomicron, intermediate-density lipoprotein (IDL) and very low-density lipoprotein (VLDL). Our developed anion-exchange high-performance liquid chromatography (AEX-HPLC) can measure all fractions of lipoproteins accurately. Our studies using AEX-HPLC showed that IDL and VLDL in type 2 diabetes were higher than non-diabetic subjects, and IDL and VLDL were higher in the order of type 2 diabetic patients with obesity, type 2 diabetic patients without obesity, and non-diabetic subjects. Here, we also describe the underlying mechanisms for development of diabetic dyslipidemia. 2019, National Center for Global Health and Medicine.

Entities:  

Keywords:  Diabetes; high-performance liquid chromatography; insulin resistance; lipoproteins; triglyceride

Year:  2019        PMID: 33330752      PMCID: PMC7731345          DOI: 10.35772/ghm.2019.01007

Source DB:  PubMed          Journal:  Glob Health Med        ISSN: 2434-9186


  35 in total

1.  Measurement of cholesterol of major serum lipoprotein classes by anion-exchange HPLC with perchlorate ion-containing eluent.

Authors:  Yuji Hirowatari; Hiroshi Yoshida; Hideo Kurosawa; Ken-iti Doumitu; Norio Tada
Journal:  J Lipid Res       Date:  2003-05-01       Impact factor: 5.922

2.  The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.

Authors:  R J HAVEL; H A EDER; J H BRAGDON
Journal:  J Clin Invest       Date:  1955-09       Impact factor: 14.808

3.  Relation of plasma high-density lipoprotein cholesterol to lipoprotein-lipase activity in adipose tissue and skeletal muscle of man.

Authors:  E A Nikkilä; M R Taskinen; M Kekki
Journal:  Atherosclerosis       Date:  1978-04       Impact factor: 5.162

4.  Prediction of coronary heart disease using risk factor categories.

Authors:  P W Wilson; R B D'Agostino; D Levy; A M Belanger; H Silbershatz; W B Kannel
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

5.  Understanding of Diabetic Dyslipidemia by Using the Anion-Exchange High Performance Liquid Chromatography Data.

Authors:  Hidekatsu Yanai; Yuji Hirowatari; Kumie Ito; Hideo Kurosawa; Norio Tada; Hiroshi Yoshida
Journal:  J Clin Med Res       Date:  2016-03-20

6.  Relevance of intermediate-density lipoprotein cholesterol to Framingham risk score of coronary heart disease in middle-aged men with increased non-HDL cholesterol.

Authors:  Kumie Ito; Hiroshi Yoshida; Hidekatsu Yanai; Hideo Kurosawa; Ryo Sato; Daisuke Manita; Yuji Hirowatari; Norio Tada
Journal:  Int J Cardiol       Date:  2013-07-11       Impact factor: 4.164

7.  Estimation of lipoprotein profile in patients with type II diabetes and its relevance to remnant lipoprotein cholesterol levels.

Authors:  Hiroshi Yoshida; Yuji Hirowatari; Hideo Kurosawa; Daisuke Manita; Hidekatsu Yanai; Kumie Ito; Norio Tada
Journal:  Atherosclerosis       Date:  2012-03-30       Impact factor: 5.162

8.  Significance of hepatic triglyceride lipase activity in the regulation of serum high density lipoproteins in type II diabetes mellitus.

Authors:  S E Kasim; K Tseng; K L Jen; S Khilnani
Journal:  J Clin Endocrinol Metab       Date:  1987-07       Impact factor: 5.958

9.  Effects of diacylglycerol on glucose, lipid metabolism, and plasma serotonin levels in lean Japanese.

Authors:  Hidekatsu Yanai; Hiroshi Yoshida; Yoshiharu Tomono; Yuji Hirowatari; Hideo Kurosawa; Akiyo Matsumoto; Norio Tada
Journal:  Obesity (Silver Spring)       Date:  2008-01       Impact factor: 5.002

Review 10.  Managing multiple cardiovascular risk factors: state of the science.

Authors:  Jon H Levine
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-10       Impact factor: 3.738

View more
  3 in total

1.  A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients.

Authors:  Hidekatsu Yanai; Hisayuki Katsuyama; Mariko Hakoshima
Journal:  Cardiol Res       Date:  2021-11-29

2.  Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study.

Authors:  Hidekatsu Yanai; Hisayuki Katsuyama; Mariko Hakoshima
Journal:  Biomedicines       Date:  2022-02-08

Review 3.  Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment.

Authors:  Hidekatsu Yanai; Hiroki Adachi; Mariko Hakoshima; Hisayuki Katsuyama
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.